Related Experiment Videos
Estimating asymptomatic duration in cancer: the AIDS connection
1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
Statistics in Medicine
|March 30, 1997
Summary
This study estimates the asymptomatic period duration for cancer using methods from acquired immunodeficiency syndrome (AIDS) research. The developed non-parametric method and EM algorithm are validated through simulations and applied to breast cancer screening data.
Area of Science:
- Epidemiology
- Biostatistics
- Medical Informatics
Background:
- Chronic diseases like cancer and acquired immunodeficiency syndrome (AIDS) have asymptomatic periods before clinical manifestation.
- Estimating the duration of this asymptomatic phase is crucial for predicting disease progression and optimizing screening strategies.
Purpose of the Study:
- To adapt methodologies from AIDS research for estimating the asymptomatic period duration in cancer.
- To introduce a novel non-parametric estimation method for the asymptomatic period in cancer, applicable to periodically screened cohorts.
Main Methods:
- Development of an Expectation-Maximization (EM) algorithm for likelihood maximization.
- Adaptation of AIDS-derived statistical methods for cancer natural history studies.
- Simulation studies to evaluate algorithm performance and the impact of smoothing techniques.
Main Results:
- The proposed non-parametric method, utilizing an EM algorithm, effectively estimates asymptomatic period duration.
- The method's performance was investigated through simulations, showing its viability.
- Adaptation for low-prevalence datasets and application to the HIP breast cancer screening trial data were successful.
Conclusions:
- The study successfully bridges AIDS and cancer research by providing a robust method for estimating asymptomatic periods in cancer.
- The developed EM algorithm offers a valuable tool for cancer screening and natural history research.
- The method's applicability to real-world data, such as the HIP breast cancer trial, highlights its practical significance.